Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187159 · ClinicalTrials.gov registry record · Phase 3
Treatment of Pain Associated With Fibromyalgia
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,270
- Enrollment target
NCT02187159: Completed Phase 3 study, sponsored by Daiichi Sankyo.
NCT02187159 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,270 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02187159, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,270 participants
- Enrollment target
Study Summary
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.
Primary Outcome
The patient reported pain intensity daily (over the past 24 hours) on a scale of 0 = no pain to 10 = worst possible pain. The daily pain scores were averaged over 7 days to calculate the weekly ADPS.
Interventions
- DRUG Placebo tablet
- DRUG Pregabalin
- DRUG Placebo capsule
- DRUG DS-5565
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,270 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-07-07 |
| Phase | Phase 3 |
What the finished NCT02187159 record still lists
NCT02187159 is an interventional study that assigns participants to a tested intervention. Its 1,270 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo tablet is the first listed.
NCT02187159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02187159 about?
NCT02187159 is a clinical study titled "Treatment of Pain Associated With Fibromyalgia". The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain ov...
What is the current status of trial NCT02187159?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,270 participants. The study started on 2014-11. Estimated completion is 2016-07-07.
What interventions are being tested in trial NCT02187159?
The interventions under investigation include: Placebo tablet (DRUG), Pregabalin (DRUG), Placebo capsule (DRUG), DS-5565 (DRUG).
Who is sponsoring clinical trial NCT02187159?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02187159's enrollment target sits among peer trials
1,270 202nd of 2000 higher than 1,799 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia